Novartis files for approval of its new CAR-T cell therapy in Europe – The Pharma Letter
The Pharma Letter |
Novartis files for approval of its new CAR–T cell therapy in Europe
The Pharma Letter In August, Swiss pharma giant Novartis won the race to market a CAR T-cell-directed therapy, receiving US Food and Drug Administration approval for its Kymriah, which the company has said is expected to achieve sales of $1 billion or more. This was … Novartis files CAR–T in Europe in broader use than Gilead rival Novartis files CAR–T therapy in Europe Novartis seeks European approval for cell therapy Kymriah |
